Friday, 14 April 2017

Surprise FDA Rejection Will Sting This Biotech

A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.

from WSJ.com: Markets http://ift.tt/2pB7sCO
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)